Survey Study to Identify the Maximum Acceptable Numbers of 2 mm and 3 mm Mini-Tablets for Short-, Middle-, and Long-Term Treatments in Acutely and Chronically Sick Children of Different Age Groups Below 18 Years
Open Access
- 26 June 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (7) , 834
Abstract
Background/Aims: This preference study aimed to identify the maximum number of mini-tablets of two different sizes that children and adolescents would be willing to take, and parents, nurses, and pediatricians would be willing to administer to children and adolescents. Methods: A total of 336 participants (24 per cohort) were stratified into 14 cohorts: Acutely and chronically sick children/adolescents aged 6–<12 years (y) and 12–<18 y, parents of acutely and chronically sick children/adolescents aged 0–<2 y, 2–<6 y, 6–<12 y, and 12–<18 y, nurses, and pediatricians. After participants were shown seven different numbers of 2 and 3 mm mini-tablets, they were asked to assess the maximum number acceptable for short-, middle-, and long-term treatment using cohort-specific questionnaires. Results: Within all groups and treatment durations, the specified maximum accepted number of 2 mm mini-tablets was higher than the number of 3 mm mini-tablets. The maximum number of mini-tablets acceptable to the participants increased with increasing age of the children and ranged from 40–500 (30–400) for the 2 mm (3 mm) mini-tablets. With increasing duration of treatment, a lower maximum number of mini-tablets was considered tolerable. Chronically sick children were willing to take higher numbers of mini-tablets than acutely sick children. The maximum accepted numbers of mini-tablets specified by pediatric patients, parents, and healthcare professionals were similar for each age group; however, pediatricians consistently specified slightly higher numbers of mini-tablets than parents and nurses. Conclusions: The study demonstrated that even a high number of mini-tablets would be well-accepted by children during middle- or long-term treatment.Keywords
Funding Information
- Department of General Pediatrics, Neonatology and Pediatric Cardiology of University Hospital Duesseldorf, Germany
- University Hospital Duesseldorf, Germany
This publication has 20 references indexed in Scilit:
- The revival of the mini-tablets: Recent advancements, classifications and expectations for the futureEuropean Journal of Pharmaceutics and Biopharmaceutics, 2025
- A Composite Endpoint for Acceptability Evaluation of Oral Drug Formulations in the Pediatric PopulationTherapeutic Innovation & Regulatory Science, 2022
- Paediatric specific dosage forms: Patient and formulation considerationsInternational Journal of Pharmaceutics, 2022
- Acceptability of small-sized oblong tablets in comparison to syrup and mini-tablets in infants and toddlers: A randomized controlled trialEuropean Journal of Pharmaceutics and Biopharmaceutics, 2021
- Acceptability of Multiple Uncoated Minitablets in Infants and Toddlers: A Randomized Controlled TrialThe Journal of Pediatrics, 2018
- Methodologies for assessing the acceptability of oral formulations among children and older adults: a systematic reviewDrug Discovery Today, 2018
- Acceptability of Uncoated Mini-Tablets in Neonates—A Randomized Controlled TrialThe Journal of Pediatrics, 2015
- Formulations for children: problems and solutionsBritish Journal of Clinical Pharmacology, 2015
- Favorable Acceptance of Mini-Tablets Compared with Syrup: A Randomized Controlled Trial in Infants and Preschool ChildrenThe Journal of Pediatrics, 2013
- Defining chronic diseases and health conditions in childhood (0–18 years of age): national consensus in the NetherlandsEuropean Journal of Pediatrics, 2008